BackEton Pharmaceuticals Overview

Eton Pharmaceuticals Common Stock

Track Eton Pharmaceuticals's common stock ($28K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$28000.00
↑ 3.70% YoYΔ $1000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Eton Pharmaceuticals Common Stock History

Loading

Eton Pharmaceuticals vs. peers: Common Stock Comparison

Loading

Eton Pharmaceuticals Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Eton Pharmaceuticals (ETON) FAQ

Eton Pharmaceuticals's common stock stands at $28K as of June 2026. That compares with $27K in the prior-year period — up 3.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Eton Pharmaceuticals reported $28K in common stock versus $27K a year earlier — a 3.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $27K in the prior-year period — up 3.7% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Eton Pharmaceuticals's common stock evolved across reporting periods, while the comparison chart places ETON next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, common stock is commonly used to spot outliers. Eton Pharmaceuticals's reading of $28K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.